Precigen, Inc.(NASDAQ : XON)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||1.29%||8.63||0.7%||$603.27m|
|REGN||Regeneron Pharmaceuticals, Inc.||-1.21%||645.26||2.7%||$516.44m|
|GILD||Gilead Sciences, Inc.||-0.77%||70.78||1.0%||$418.38m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.17%||186.78||1.9%||$230.17m|
|ISEE||IVERIC bio, Inc.||-2.23%||16.00||0.0%||$184.96m|
|LIFE||aTyr Pharma, Inc.||-7.68%||9.47||3.2%||$128.59m|
|KDMN||Kadmon Holdings, Inc.||-0.62%||8.77||0.9%||$127.36m|
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, Trans Ova and Human Biotherapeutics. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Trans Ova segment includes provides advanced reproductive technologies. The Human Biotherapeutics segment accelerated recognition of previously deferred revenue upon the mutual termination of a collaboration with Castle Creek in 2020. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.